Abstract: The present invention provides a subunit vaccine composition for African swine fever, and a preparation therefor and use thereof, which fall within the technical field of animal vaccines and veterinary biological products. The vaccine comprises an exterior envelope protein CD2V derived from African swine fever virus and an exterior envelope capsid protein p72 derived from African swine fever virus and a pharmaceutically acceptable adjuvant. The method for preparing the vaccine comprises: 1) preparing the exterior envelope protein CD2V derived from African swine fever virus and the exterior envelope capsid protein p72 derived from African swine fever virus; 2) mixing the exterior envelope protein CD2V derived from African swine fever virus with the exterior envelope capsid protein p72 derived from African swine fever virus prepared in step 1), so as to prepare an antigen solution; and 3) emulsifying the antigen solution and ISA 201 VG at a volume ratio of 46:54.

Abstract: A method for purifying ferric chloride, the method including: 1) adding an oxidant to an aqueous solution of an iron-containing chloride for oxidation of Fe2+, to yield a ferric chloride solution; 2) adding industrial hydrochloric acid and butyl acetate to the ferric chloride solution, shaking and resting a mixture of the ferric chloride solution, the industrial hydrochloric acid, and butyl acetate for phase separation, to yield an organic phase and an aqueous phase; 3) adding a stripping agent to the organic phase, shaking, and resting a mixture of the stripping agent and the organic phase; and collecting an aqueous phase including ferric chloride; and 4) evaporating and concentrating the aqueous phase including ferric chloride, removing butyl acetate, to yield purified ferric chloride.

Abstract: A method for purifying ferric chloride, the method including: 1) adding an oxidant to an aqueous solution of an iron-containing chloride for oxidation of Fe2+, to yield a ferric chloride solution; 2) adding industrial hydrochloric acid and butyl acetate to the ferric chloride solution, shaking and resting a mixture of the ferric chloride solution, the industrial hydrochloric acid, and butyl acetate for phase separation, to yield an organic phase and an aqueous phase; 3) adding a stripping agent to the organic phase, shaking, and resting a mixture of the stripping agent and the organic phase; and collecting an aqueous phase including ferric chloride; and 4) evaporating and concentrating the aqueous phase including ferric chloride, removing butyl acetate, to yield purified ferric chloride.

Abstract: The disclosure discloses a porcine epidemic diarrhea virus S protein and a subunit vaccine thereof as well as a method for preparing the subunit vaccine and application thereof. The vaccine contains 30˜220 ?g of a recombinant porcine epidemic diarrhea virus S protein and a pharmaceutically acceptable ISA 201 VG adjuvant. A method for preparing the subunit vaccine comprises the following steps: (1) cloning the recombinant porcine epidemic diarrhea virus S protein; (2) expressing and purifying the recombinant porcine epidemic diarrhea virus S protein; (3) preparing the recombinant porcine epidemic diarrhea virus S protein prepared in (2) into a water phase; (4) emulsifying the water phase and the ISA 201 VG adjuvant in a volume ratio of 46:54 to obtain a vaccine. The vaccine is high in safety, good in immunogenicity, stable in batches, low in production cost and strong in immunogenicity.

Abstract: The disclosure discloses a porcine epidemic diarrhea virus S protein and a subunit vaccine thereof as well as a method for preparing the subunit vaccine and application thereof. The vaccine contains 30˜220 ?g of a recombinant porcine epidemic diarrhea virus S protein and a pharmaceutically acceptable ISA 201 VG adjuvant. A method for preparing the subunit vaccine comprises the following steps: (1) cloning the recombinant porcine epidemic diarrhea virus S protein; (2) expressing and purifying the recombinant porcine epidemic diarrhea virus S protein; (3) preparing the recombinant porcine epidemic diarrhea virus S protein prepared in (2) into a water phase; (4) emulsifying the water phase and the ISA 201 VG adjuvant in a volume ratio of 46:54 to obtain a vaccine. The vaccine is high in safety, good in immunogenicity, stable in batches, low in production cost and strong in immunogenicity.

Abstract: A vacuum circuit interrupter having a pole unit structure and an operating mechanism structured to move the vacuum circuit interrupter contacts between a first, closed position, wherein a movable contact is coupled to, and in electrical communication with, a fixed contact, and a second, open position wherein the movable contact is spaced from, and not in electrical communication with, the fixed contact, as well as being structured to rotate a housing assembly rotatable portion between a first position, wherein a rotatable terminal is coupled to, and in electrical communication with, a line terminal, and a second position, wherein the rotatable terminal is coupled to, and in electrical communication with, a grounded terminal.

Abstract: A vacuum circuit interrupter having a pole unit structure and an operating mechanism structured to move the vacuum circuit interrupter contacts between a first, closed position, wherein a movable contact is coupled to, and in electrical communication with, a fixed contact, and a second, open position wherein the movable contact is spaced from, and not in electrical communication with, the fixed contact, as well as being structured to rotate a housing assembly rotatable portion between a first position, wherein a rotatable terminal is coupled to, and in electrical communication with, a line terminal, and a second position, wherein the rotatable terminal is coupled to, and in electrical communication with, a grounded terminal.